CliffBio
small molecule

ACETAMINOPHEN AND IBUPROFEN

ACETAMINOPHEN; IBUPROFEN

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameACETAMINOPHEN AND IBUPROFEN
Active ingredientACETAMINOPHEN; IBUPROFEN
Strength250MG;125MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2026
Marketing statusOTC

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.